Nabil Lally Highlights Real- Time Clinical Data at DCAT 2025 Nabil Lally from Quotient Sciences presented at DCAT Week 2025 on leveraging real-time clinical data to revolutionize formulation development. Discover how the Translational Pharmaceutics platform is transforming early- phase drug development. The Challenge: Traditional Drug Development Bottlenecks Traditional drug development often follows a rigid, sequential path, leading to significant delays and increased costs. This linear approach can hinder progress and extend the time it takes for essential medicines to reach patients. 1 Sequential Phases Distinct, isolated stages from discovery to clinical trials. 2 Delayed Feedback Insights from clinical data are often gathered only after phase completion. 3 High Failure Rates Inability to adapt formulations mid- study increases risks. Quotient's Translational Pharmaceutics Platform Quotient Sciences' innovative platform integrates drug product manufacturing and clinical testing, enabling real-time adjustments and accelerating development. Integrated Approach Combines formulation, manufacturing, and clinical trials. Real-Time Data Immediate insights on drug absorption and patient response. Adaptive Design Allows for mid-study formulation adjustments. Unlocking Speed and Certainty Nabil Lally highlighted how real-time clinical data provides unprecedented speed and certainty in drug formulation. Accelerated Timelines Compresses development by 6-12 months, bringing drugs to market faster. Reduced Costs Optimizes resource allocation by minimizing study iterations. Improved Decision- Making Data-driven insights enable agile adjustments and reduce failure risks. Proven Success: Case Studies With over 300 successful programs, Quotient Sciences has demonstrated the profound impact of their approach. Oncology Breakthrough Optimal formulation for a cancer drug identified within a single clinical study. Pediatric Dosage Accurate dosage adjustments for a pediatric drug based on real-time patient data. Broad Application Applicable across various therapeutic areas, from small molecules to biologics. Regulatory Acceptance and Fast Tracks The paradigm shift towards real-time data is gaining traction with regulatory bodies, facilitating faster submissions and approvals. Streamlined Submissions Real-time data supports fast-track designations like Breakthrough Therapy and Fast Track. Regulatory agencies are increasingly amenable to mid-study changes when rigorously documented with immediate data. Key Takeaways from DCAT 2025 Nabil Lally's presentation underscored the transformative potential of integrating real-time data into drug development. Accelerated Timelines Significant reduction in development duration. Data-Driven Precision Enhanced formulation accuracy with immediate feedback. Strategic Advantage Positioning for faster regulatory pathways. Driving the Future of Drug Development Quotient Sciences continues to lead the way in early-phase drug development, promising a future of faster, more efficient, and more certain drug delivery. Learn More About Nabil Lally